Edition:
United States

People: Emergent BioSolutions Inc (EBS)

EBS on New York Consolidated

35.49USD
17 Aug 2017
Change (% chg)

-- (--)
Prev Close
$35.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
303,084
52-wk High
$36.95
52-wk Low
$24.47

Abdun-Nabi, Daniel 

Mr. Daniel J. Abdun-Nabi is President, Chief Executive Officer, Director of the Company. Mr. Abdun-Nabi served as our president and chief operating officer. Mr. Abdun-Nabi previously served as our secretary from December 2004 to January 2008, our senior vice president, corporate affairs and general counsel from December 2004 to April 2007 and our vice president and general counsel from May 2004 to December 2004. Mr. Abdun-Nabi served as general counsel for IGEN International, Inc., a biotechnology company, and its successor BioVeris Corporation, from September 1999 to May 2004. Prior to joining IGEN, Mr. Abdun-Nabi served as senior vice president, legal affairs, general counsel and secretary of North American Vaccine, Inc. He is the Chairman of the Maryland Life Sciences Advisory Board. In August 2016, Mr. Abdun-Nabi joined the boards of REGENXBIO Inc., a publicly-traded biotech company, and Aptevo Therapeutics Inc., a publicly-traded biotech company which focuses on bringing novel oncology and hematology therapeutics to market. Mr. Abdun-Nabi received a Master of Law in Taxation from Georgetown University Law Center, a J.D. from the University of San Diego School of Law and a B.A. in political science from the University of Massachusetts, Amherst.

Basic Compensation

Total Annual Compensation, USD 776,629
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 2,408,440
Fiscal Year Total, USD 3,185,070

Options Compensation

  Quantity Market Value
Exercisable 25,900 --
Unexercisable 11,100 --
Exercised 11,576 119,966.00
Name Fiscal Year Total

Fuad El-Hibri

2,428,930

Daniel Abdun-Nabi

3,185,070

Robert Kramer

1,475,060

Adam Havey

988,069

Ronald Richard

382,493

Sue Bailey

331,993
As Of  30 Dec 2016